May 2018, Medicilon clinical pathology laboratory was qualified in the interventricular quality evaluation of Shanghai Center for Clinical Laboratory.
Innovative Research and Development Services Professional Committee established
Medicilon is delighted to announce that Dr. Xiaodong (Mark) Zhang has joined us to further develop the growing Preclinical Research accounts.
Welcome Dr。 Wenxin Dong to Join the Department of Efficacy。
As a one-stop pharmaceutical R & D outsourcing CRO, by providing the information on cardio toxicity assessment in the early period, this could help Medicilon for screening higher cardiac safety factor candidate compound through our chemical, pharmacodynamics, pharmaceutical and preparation services or platforms。